FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2968968970> ?p ?o ?g. }

• W2968968970 endingPage "557" @default.
• W2968968970 startingPage "548" @default.
• W2968968970 abstract "Abstract The CD‐20 antibody rituximab is a standard component of treatment of non‐Hodgkin B‐cell lymphomas, including diffuse large B‐cell lymphoma (DLBCL). Primary DLBCL of the central nervous system, also called primary central nervous system lymphoma (PCNSL), is a DLBCL confined to the central nervous system. There has been debate whether intravenous rituximab accumulates sufficiently in the central nervous system to exert an effect. In this systematic review, we assess the benefits and harms of rituximab in the treatment of immunocompetent patients with PCNSL. By searching MEDLINE, CENTRAL, and ClincialTrials.gov up to March 2019, we identified randomized controlled trials (RCTs) investigating the effect of rituximab in patients with PCNSL. We extracted study characteristics and results, assessed risk of bias, performed trial‐level random‐effects meta‐analyses, and graded the certainty of evidence. The protocol was registered with PROSPERO (CRD42019121965). Main outcomes were overall survival (time to death), progression‐free survival (time to progression or death), quality of life, grades 3 and 4 toxicity, and treatment‐related mortality. We included two RCTs with a total of 343 participants. Overall survival was not statistically significantly improved (HR 0.76; 95% CI, 0.52‐1.12; low certainty), with 187 fewer to 39 more deaths after 2 years in 1000 treated patients. Low certainty of evidence indicated that rituximab improved progression‐free survival (HR 0.65; 95% CI, 0.45‐0.95), which translated into 137 fewer progressions or deaths after 2 years in 1000 treated patients (231 to 18 fewer). None of the RCTs provided data on quality of life. We found no evidence that rituximab increased grades 3 and 4 toxicity or treatment‐related mortality (RR 0.53; 95% CI, 0.20‐1.37; low certainty). Overall, the available evidence suggests with low certainty that rituximab in combination with methotrexate‐based chemotherapy may improve progression‐free survival in immunocompetent patients with newly diagnosed PCNSL, the pooled effect estimates did not show evidence for improvement of overall survival." @default.
• W2968968970 created "2019-08-22" @default.
• W2968968970 creator A5007493880 @default.
• W2968968970 creator A5009234092 @default.
• W2968968970 creator A5010948621 @default.
• W2968968970 creator A5011578307 @default.
• W2968968970 creator A5017224763 @default.
• W2968968970 creator A5020447255 @default.
• W2968968970 creator A5022062856 @default.
• W2968968970 creator A5036985315 @default.
• W2968968970 creator A5048397536 @default.
• W2968968970 creator A5049307026 @default.
• W2968968970 creator A5074510368 @default.
• W2968968970 creator A5075098080 @default.
• W2968968970 creator A5082526059 @default.
• W2968968970 creator A5084978936 @default.
• W2968968970 creator A5090780331 @default.
• W2968968970 date "2019-10-09" @default.
• W2968968970 modified "2023-10-01" @default.
• W2968968970 title "Rituximab in primary central nervous system lymphoma—A systematic review and meta‐analysis" @default.
• W2968968970 cites W1568033114 @default.
• W2968968970 cites W1978506340 @default.
• W2968968970 cites W1980472079 @default.
• W2968968970 cites W1989124191 @default.
• W2968968970 cites W1999717985 @default.
• W2968968970 cites W2007540726 @default.
• W2968968970 cites W2047586716 @default.
• W2968968970 cites W2052229537 @default.
• W2968968970 cites W2058015212 @default.
• W2968968970 cites W2111322227 @default.
• W2968968970 cites W2111412973 @default.
• W2968968970 cites W2126778627 @default.
• W2968968970 cites W2126959402 @default.
• W2968968970 cites W2136060045 @default.
• W2968968970 cites W2145453495 @default.
• W2968968970 cites W2149603266 @default.
• W2968968970 cites W2160305510 @default.
• W2968968970 cites W2165010366 @default.
• W2968968970 cites W2178360273 @default.
• W2968968970 cites W2314481096 @default.
• W2968968970 cites W2338036651 @default.
• W2968968970 cites W2662929969 @default.
• W2968968970 cites W2790268129 @default.
• W2968968970 cites W2845112623 @default.
• W2968968970 cites W2890695763 @default.
• W2968968970 cites W2906764941 @default.
• W2968968970 cites W2917478934 @default.
• W2968968970 cites W4254349653 @default.
• W2968968970 doi "https://doi.org/10.1002/hon.2666" @default.
• W2968968970 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31418878" @default.
• W2968968970 hasPublicationYear "2019" @default.
• W2968968970 type Work @default.
• W2968968970 sameAs 2968968970 @default.
• W2968968970 citedByCount "49" @default.
• W2968968970 countsByYear W29689689702020 @default.
• W2968968970 countsByYear W29689689702021 @default.
• W2968968970 countsByYear W29689689702022 @default.
• W2968968970 countsByYear W29689689702023 @default.
• W2968968970 crossrefType "journal-article" @default.
• W2968968970 hasAuthorship W2968968970A5007493880 @default.
• W2968968970 hasAuthorship W2968968970A5009234092 @default.
• W2968968970 hasAuthorship W2968968970A5010948621 @default.
• W2968968970 hasAuthorship W2968968970A5011578307 @default.
• W2968968970 hasAuthorship W2968968970A5017224763 @default.
• W2968968970 hasAuthorship W2968968970A5020447255 @default.
• W2968968970 hasAuthorship W2968968970A5022062856 @default.
• W2968968970 hasAuthorship W2968968970A5036985315 @default.
• W2968968970 hasAuthorship W2968968970A5048397536 @default.
• W2968968970 hasAuthorship W2968968970A5049307026 @default.
• W2968968970 hasAuthorship W2968968970A5074510368 @default.
• W2968968970 hasAuthorship W2968968970A5075098080 @default.
• W2968968970 hasAuthorship W2968968970A5082526059 @default.
• W2968968970 hasAuthorship W2968968970A5084978936 @default.
• W2968968970 hasAuthorship W2968968970A5090780331 @default.
• W2968968970 hasConcept C126322002 @default.
• W2968968970 hasConcept C143998085 @default.
• W2968968970 hasConcept C168563851 @default.
• W2968968970 hasConcept C2778559949 @default.
• W2968968970 hasConcept C2779338263 @default.
• W2968968970 hasConcept C2780653079 @default.
• W2968968970 hasConcept C2781173314 @default.
• W2968968970 hasConcept C535046627 @default.
• W2968968970 hasConcept C71924100 @default.
• W2968968970 hasConcept C95190672 @default.
• W2968968970 hasConceptScore W2968968970C126322002 @default.
• W2968968970 hasConceptScore W2968968970C143998085 @default.
• W2968968970 hasConceptScore W2968968970C168563851 @default.
• W2968968970 hasConceptScore W2968968970C2778559949 @default.
• W2968968970 hasConceptScore W2968968970C2779338263 @default.
• W2968968970 hasConceptScore W2968968970C2780653079 @default.
• W2968968970 hasConceptScore W2968968970C2781173314 @default.
• W2968968970 hasConceptScore W2968968970C535046627 @default.
• W2968968970 hasConceptScore W2968968970C71924100 @default.
• W2968968970 hasConceptScore W2968968970C95190672 @default.
• W2968968970 hasIssue "5" @default.
• W2968968970 hasLocation W29689689701 @default.
• W2968968970 hasOpenAccess W2968968970 @default.
• W2968968970 hasPrimaryLocation W29689689701 @default.

• next